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Introduction
Current treatments for most metastatic cancers have poor out-
comes due to the dispersed nature of the disease, toxicity of the
therapeutic agent and inaccessibility of some of the tumour sites.
The development of a successful treatment for metastatic cancer
has long been one of the most elusive goals of cancer gene ther-
apy. While many systems have been developed that induce high
levels of apoptosis in cancer tissue, selectively delivering the ther-
apeutic transgene to widely disseminated metastatic sites via the
blood stream has often proven unachievable. The hurdles that a
therapeutic vector faces in the blood stream are manifold and
include the innate and adaptive immune response, potential
adsorption to erythrocytes and clearance by specialized cells in the
liver and spleen.
Recently, mesenchymal stem cells (MSCs) have begun to show
promise as a potential delivery vector for a number of reasons.
These cells may be transduced to high levels with adenovirus and
lentivirus [1]. They have immune privilege as they do not express
the costimulatory molecules B7-1, B7-2, CD40 and CD40 ligand
[2–4]. This property of MSCs may be important in protecting the
cells from immune responses against the vector or transgene 
that they are carrying. These cells also secret prostaglandin E2,
transforming growth factor  and hepatocyte growth factor, which
Mesenchymal stem cells expressing TRAIL lead to tumour
growth inhibition in an experimental lung cancer model
Andrea Mohr a, #, Mark Lyons b, #, Laura Deedigan a, Tina Harte b, Georgina Shaw b, Linda Howard b,
Frank Barry b, Tim O’Brien b, c, Ralf Zwacka a, b *
a Molecular Therapeutics Group, National Centre for Biomedical Engineering Science, 
National University of Ireland, Galway, Ireland
b Regenerative Medicine Institute (REMEDI), National Centre for Biomedical Engineering Science, 
National University of Ireland, Galway, Ireland
c Department of Medicine, National University of Ireland, Galway, Ireland
Received: August 14, 2007; Accepted: March 17, 2008
Abstract
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regulate the immune response of T cells to novel antigens thereby
decreasing the chances of a cytotoxic T-cell response to the trans-
duced cells [2, 5]. MSCs have also been shown to migrate towards
tumours in response to chemokines such as stromal cell-derived
factor (SDF)-1, hepatocyte growth factor (HGF) and vascular
endothelial growth factor (VEGF) produced by tumour cells [6, 7].
MSCs are also capable of extravasating towards tumours when
introduced into the organism via the local blood stream [8]. It
appears that tumour growth requires formation of supportive mes-
enchymal stroma and that the tumour stroma formation is similar
to tissue remodelling during wound healing that is characterized by
high proliferation of mesenchymal cells. MSCs have greater poten-
tial and capacity to contribute to the population of stromal cells
than fully differentiated fibroblasts. This allows the development of
therapeutic strategies that are based on the local production of
tumouricidal biological agents by gene-manipulated MSCs [9].
In order to use MSCs as transgene delivery vehicles they would
ideally be transduced with an agent that will infect a high percent-
age of MSCs and express high levels of transgene. Adenovirus
type 5 (Ad5) has undergone extensive evaluation as a gene therapy
vector due to its ease of production to high titre, high levels of
transgene expression and the potential to produce the virus to
good manufacturing practice (GMP) standards [10]. Adenovirus
also has a good safety profile and has been used in a wide range
of clinical trials though high doses of the virus can induce poten-
tially lethal immune responses [11, 12]. Also, in the context of sys-
temic delivery adenovirus may be hampered by innate and adaptive
immune responses [13, 14]. Up to 96% of Western healthy adults
have antibodies against Ad5 with approximately 55% of these
being neutralizing  [15]. Repeat administration of the virus into
donors results in high levels of vector-specific antibodies, which
impair transgene delivery [16]. Furthermore, destruction of trans-
genic protein producing cells by the immune system has been
shown to have hampered many of the adenovirus-based gene
therapy strategies in the past [17]. Adenovirus is bound and
sequestered by erythrocytes at titres up to those that may be
safely administered to a human patient [18]. These issues have
been addressed by other workers by modifying the surface epi-
topes of the virus capsid or masking the virus with synthetic poly-
mers [19–22]. However, these technologies, while promising,
have not yet been shown to be capable of bypassing all of the
body’s immune defences. Given the particular properties of MSCs
it is envisaged that these cells may act as cellular vectors and
transgenic protein factories without inducing an immune
response. MSCs have previously been shown to be effective anti-
cancer agents when transduced with adenoviruses expressing a
range of transgenes including interferon (IFN)- and interleukin
(IL)-12 as well as oncolytic adenovirus [8, 23, 24].
Many of the current therapeutic modalities for the treatment of
cancer are limited by their toxicity to healthy tissue. Consequently,
tumour-specific apoptosis-inducing agents are being sought and
one potentially promising candidate that fulfils this criterion is
tumour necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL). Healthy tissue has been shown to express both the active
and decoy receptors for TRAIL and is resistant to TRAIL-induced
apoptosis, interestingly however, many cancer cell lines have been
shown to be sensitive to TRAIL-induced apoptosis [25, 26].
Recombinant TRAIL protein and an agonistic antibody to TRAIL-R2
have been shown to be safe for administration to humans at doses
consistent with those shown to be effective in xenograft models [27,
28]. Gene therapy approaches utilizing TRAIL have also been shown
to be effective in experimental tumour models, and murine embry-
onic stem cells expressing TRAIL have been demonstrated to be
effective in the treatment of malignant glioma in vitro [29–32].
While many tests have been performed on the suitability of
MSCs as vectors in animal models there are no published data
examining the stability and efficacy of these adenovirus-transduced
MSCs in the context of human blood from donors that have pre-
existing anti-adenovirus immunity. In this paper we describe the
ability of TRAIL expressing, adenovirus transduced, MSCs to block
tumour growth in a mouse model and to induce apoptosis in a rel-
atively TRAIL refractory epithelial lung cancer cell line (A549 cells).
We demonstrate that adenovirus-transduced MSCs do not induce
peripheral blood mononuclear cells (PBMCs) proliferation. We also
describe how these cells are capable of inducing apoptosis in A549
cells in the presence of neutralizing  antibodies, white blood cells
(WBCs) or erythrocytes at physiological concentrations, which
normally block or inhibit adenovirus-mediated transgene delivery.
Materials and methods
Reagents
All reagents were supplied by Sigma Aldrich (St. Louis, MO, USA) unless
otherwise stated. Recombinant human TRAIL was supplied by R&D
Systems (Minneapolis, MN, USA). The CD105 antibody and isotype control
were from BD Bioscience (San Jose, CA, USA). The pan-caspase inhibitor
zVAD was bought from Santa Cruz (Santa Cruz, CA, USA).
Adenovirus preparations
Three Ad5-based vectors were used in these studies, Ad.EGFP, Ad.BGal,
and Ad.TR each deleted of E1 and E3 and with a reporter gene (EGFP, 
-galactosidase), or TNF-related apoptosis-inducing factor (TRAIL)
inserted in E1 under the control of the cytomegalovirus (CMV) promoter.
All viruses were grown on 293 cells and purified by double banding on
CsCl gradients. Virus concentration was determined by plaque assay.
Isolation and expansion of human MSCs 
and cell culture
MSCs were obtained through the Regenerative Medicine Institute at the
National University of Ireland, Galway. Bone marrow aspirates were
obtained from the iliac crest of normal donors; all procedures were per-
formed with informed consent and approved by the Clinical Research
Ethical Committee at University College Hospital, Galway. MSCs were
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isolated and expanded in culture as described previously by direct plating
[33]. Aspirates were washed with medium (Dulbecco’s Modified Eagle
Medium (DMEM)-low glucose containing 1% antibiotic) and centrifuged;
the precipitated cells were suspended in medium with 10% selected foetal
bovine serum (FBS, Hyclone, South Logan, UT, USA) and plated at a final
density of approximately 3.0  105 cells/cm2. Cells were seeded in T-175
flasks and maintained at 37C with 95% humidity and 5% CO2 in the same
medium. After 5 days, red blood cells were washed off with phosphate-
buffered saline and fresh medium added. Colonies of adherent cells formed
within 9 days. At the end of primary culture, adherent colonies were
detached by treatment with 0.25% trypsin and 0.53 mM ethylenediaminete-
traacetic acid (EDTA) and hMSCs cryopreserved in 10% Dimethylsulfoxide
(DMSO)/90% FBS until used. MSCs were cultured in DMEM (low glucose)
(Sigma) 10% FBS (Hyclone), 1% Pen/Strep (= MSC medium). The ability of
cells to differentiate into osteocytes and adipocytes was confirmed before use.
Osteogenesis was induced in the presence of dexamethasone (100 nmol/l),
ascorbic acid (50 mol/l), and ß-glycerophosphate (10 nmol/l). Calcium dep-
osition was detected using Von Kossa staining. Adipogenesis was induced in
the presence of methylisobutylxanthine (0.5 mmol/l), dexamethasone 
(1 mol/l), insulin (10 g/ml) and indomethacin (200 mol/l). Accumulation
of lipid deposits was detected using Oil Red O (32). A549 cells were obtained
from ATCC and grown in Roswell Park Memorial Institute (RPMI) 10% FBS,
2 mM L-glutamine, 1% Pen/Strep. HCT116 cells were obtained from ATCC
and grown in McCoy’s 10% FBS, 1% Pen/Strep. Human primary fibroblast
were obtained from the Department of Dermatology, University of Ulm and
grown in DMEM 10% FBS, 1% Pen/Strep.
Transduction of MSCs
MSCs were plated at a density of 105 cells per well in a 6-well plate
(Sarstedt, Nuembrecht, Germany) and left to adhere overnight. Cells were
untransduced or transduced with virus at 100 pfu/cell (unless otherwise
stated) and the plates were spun at 600  g for 90 min. at 37C. The virus
was left on the cells overnight and then washed off.
MSC-mediated apoptosis induction
A549 cells were plated in 24-well plates at 105 cells per well and left
overnight to adhere. MSCs or adenovirus-transduced MSCs were then added
at a concentration of 104 cells per well (unless otherwise stated). Forty-eight
hours after the addition of MSCs, the cells were trypsinized. The supernatant,
wash fraction and trypsin/cell suspension were centrifuged at 400  g for
5 min. The supernatant was removed and the cell pellet was re-suspended
in Nicoletti assay buffer containing propidium iodide [34]. Cells were
assayed for DNA fragmentation after 24–48 hrs by flow cytometry.
Blood cell preparation
Erythrocytes were prepared by collecting blood by venepuncture of the
cephalic vein from normal donors after obtaining consent. The procedure
received ethical approval from the NUI Galway research ethics committee.
Blood was collected into syringes containing heparin anti-coagulant
buffer. The blood was centrifuged at (1350  g) for 10 min. and the
plasma was removed. The cell pellet was then washed four times with
PBS. The pellet was then re-suspended in MSC medium at physiological
concentration (5  109 cells/ml). WBC were prepared by pelleting 1 ml of
whole blood as previously described. The pellet was re-suspended in 5 ml
H2O for 20 sec. and immediately afterwards 1 ml of 6 saline was added.
The WBC were pelleted, the supernatant was discarded and the cells were
re-suspended in RPMI 1640 10% FBS, 2 mM L-glutamine, 1% Pen/Strep,
10 mM HEPES, 50 M -mercaptoethanol (PBMC medium). PBMCs were
prepared by taking blood and diluting it 1:1 in RPMI. This mixture was
then layered onto half its volume of Ficoll Hypaque Premium 
(GE Healthcare, Bucks, UK). The preparation was then spun at 800  g for 
30 min. The PBMC layer was removed using a pastette and diluted in 10 ml
PBS and centrifuged at 600  g for 5 min. The supernatant was discarded
and the cell pellet was washed in 10 ml PBS. The cells were then re-sus-
pended in PBMC medium. Serum was prepared by taking blood by
venepuncture without anti-coagulant. The blood was left to clot and then
agitated with a pipette until liquid. This suspension was then centrifuged 
at (1350  g) for 10 min. and the serum fraction was removed. The
serum was then heat inactivated at 56C for 30 min.
Stimulation of T cells
PBMCs were prepared as described above. PBMCs were then stained with
CFSE dye (Vybrant CFDA SE Cell Tracer kit; Molecular Probes, Invitrogen,
Carlsbad, CA, USA) by suspending the cells in 5 M CFSE in PBS for 
10 min. at 37C. The reaction was stopped by adding 5 vols. ice cold PBMC
medium and the cells were washed three times. The cells were then left
overnight to facilitate removal of excess dye before being used for assays.
105 CFSE-stained PBMCs were added to each well of a 96-well round bot-
tom plate. Pre-prepared untransduced or Ad-transduced MSCs were added
to these wells at a concentration of 104 MSCs per well to assess their abil-
ity to induce T-cell proliferation. As a control PBMCs were also stimulated
by the addition of 2.5 l CD3/CD28 beads (Dynal, Invitrogen, CA, USA).
Proliferation was determined after 5 days by flow cytometry, gating on the
lymphocyte population.
Western blot analysis
Cells were harvested by trypsinization and lysed in cell lysis buffer con-
taining 50 mM Tris pH 7.4, 10% glycerol, 0.5% NP40, 150 mM NaCl, 
1 mM MgCl2, 1 mM CaCl2, 1 mM KCl and Complete Mini Protease
Inhibitors (Roche, Basel, Switzerland). Twenty-five g protein was
loaded per track. Cell lysates were subjected to 10% SDS-PAGE. Protein
detection was performed by diluting anti-human Trail Ab (Peprotech,
Rocky Hill, NJ, USA) 1:200 or anti-CuZnSOD Ab (The Binding Site,
Birmingham, UK) 1:2000 in TBS 0.1% Tween, 5% Marvel milk powder
(Premier Brands, Spalding, UK). The secondary anti-rabbit IgG antibody
(TRAIL) and anti-sheep IgG antibody (CuZnSOD) conjugated to horse-
radish-peroxidase (Santa Cruz) were added at a dilution of 1:5000. For
the E1A Western blot a mouse-anti-E1A antibody (BD Bioscience,
Franklin Lakes, NJ, USA) diluted 1:500 and an antimouse IgG antibody
conjugated to horse-radish-peroxidase (Santa Cruz) diluted 1:2000 were
used. Detection was performed using ECL Western blot chemilumines-
cence reagent (GE Healthcare) and a Fluorochem imaging system.
Quantitative polymerase chain reaction
DNA samples were prepared for Q-PCR by extraction of cell lysates with
a QIamp DNA Minikit (Qiagen, Hilden, Germany). Real-time PCR was
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carried out using the ABI Prism 7000 sequence detector (Applied
Biosystems, Warrington, UK). PCR primers for the Ad5 knob–turn region
(KT) of the fibre gene were designed using Primer Express software
(Applied Biosystems). These were KTf (forward primer TGGCTGTTAAAG-
GCAGTTTGG), KTr (reverse primer GCACTCCATTTTCGTCAAATCTT). A
final reaction volume of 25 l consisted of 12.5 l SYBR Green Jump
Start Taq Ready Mix, 2.5 l of each primer (10 M) and 5 l of sample.
The standard curve consisted of 10-fold serial dilutions of virus in 100 l
of PBS mixed with 100 l lysis buffer (Promega, Southampton, UK) con-
taining the relevant number and type of cells. All samples were DNA
extracted and amplified in triplicate under the following conditions: 50C
for a 2-min. hold, 95C for a 10-min. hold, and then 40 cycles of 95C 
for 15 sec. and 60C for 1 min. The results were analysed with the
Sequence Detection System software (Applied Biosystems).
Neutralization assay
The neutralization properties of the sera were determined by incubating
107 pfu Ad.EGFP in serum diluted 1:10 or 1:100, final volume 500 l, for
30 min. at 37C. The suspension was then added to A549 cells that had
been seeded the previous day at 105 cells per 24-well plate well. The sam-
ples were assayed for EGFP expression after 48 hrs by flow cytometry.
Cell tracker green (CTG) staining
1.2  106 A549 cells were re-suspended in RPMI containing 25 M Cell
Tracker Green (Molecular Probes, Invitrogen) and incubated at 37C for 30
min. Cells were pelleted and the supernatant discarded. The cells were then
washed in 1 ml RPMI 10% FCS, 2 mM L-glutamine, 1% Pen/Strep. In
assays employing CTG, cells were plated at 105 cells per well of a 24-well
plate 6 hrs before the assay was started to minimize the effects of dye
dilution due to the fast growth rate of the cells.
Animal studies
Ten-week-old female Balb/c nu/nu mice (B&K Universal, Hull, UK) were
injected with 5  106 A549 cells in 200 l PBS. After 1 week and a tumour
size of ca. 100 mm3, the tumours were directly injected with 1  106 MSC
that had been transduced with Ad.TR (100 pfu/cell) and Ad.EGFP (100
pfu/cell), respectively, 24 hrs earlier. The transduced MSCs were exten-
sively washed, trypsinized and washed again before their in vivo use. The
growth of the tumours was then followed over 3 weeks. Three different
diameters of each tumour were measured once a week. The tumour vol-
ume was calculated using the formula: 3,14158/ 6*(d1*d2*d3). Five ani-
mals per group were analysed. Two additional animals with A549
xenografts were injected with untransduced MSCs. Their tumour growth
was indistinguishable from those treated with MSC.EGFP (data not
shown). The animal studies were performed according to national laws and
covered by license from the Irish government.
Statistical analysis
Experimental values are expressed as mean value ± standard deviation. For
significance analyses, Student’s t-tests were used and P < 0.05 (*) was
considered significant and P < 0.001 (**) as highly significant.
Results
Adenovirus expressing TRAIL induces apoptosis
in TRAIL resistant A549 cells
In order to determine the potential of adenovirus expressing
TRAIL (Ad.TR), of which a schematic view is depicted in Fig. 1A,
as a cancer cell apoptosis inducing agent in A549 lung carcinoma
cells we compared this virus to recombinant TRAIL protein (rTR).
A549 cells are traditionally classed as TRAIL resistant. At doses of
10 ng/ml rTR apoptosis levels were only approximately 4 percent-
age points (%) above background equivalent to cells infected with
Ad.TR at 1 pfu/cell. In contrast, A549 cells exposed to Ad.TR at
100 pfu/cell demonstrated levels of apoptosis of approximately
45% above background after 48 hrs. The toxicity of the virus
appeared to be transgene specific as the levels of apoptosis in
cells exposed to adenovirus expressing -galactosidase (Ad.BGal)
at similar pfu were only approximately 3.5% above background
(Fig. 1B). Thus, membrane- bound TRAIL has a significantly
higher tumour cell-killing activity than rTR, which led us to test
MSCs that have been shown to infiltrate growing tumours as a
potential cellular carrier of full-length TRAIL.
MSCs express transgenic TRAIL protein
and induce apoptosis in A549 cells
In order to determine whether MSCs could be used as a potential
vehicle for adenovirus-expressed TRAIL, MSCs were transduced
with Ad.EGFP (MSC.EGFP) and Ad.TR (MSC.TRAIL) at 100 pfu/cell
and compared to untransduced MSCs. The images in Fig. 2A,
which were taken 48 hrs after transduction, demonstrate that ade-
noviral transduction did not change the overall morphology of the
cells and transduction with Ad.EGFP gave rise to green 
fluorescent signals in almost all cells (Fig. 2A). Further quantification
of the EGFP signal by fluorescence activated cell sorting (FACS)
analysis revealed that 99% of all cells were expressing the trans-
gene (Fig. 2B). Subsequently, MSCs transduced with Ad.BGal and
Ad.TR at 100 pfu/cells were harvested and protein lysates prepared
48 hrs after transduction. In Western analysis, only cells trans-
duced with Ad.TR demonstrated detectable levels of the TRAIL pro-
tein (Fig. 2C). Next, we tested whether MSCs would be resistant to
the effects of the expressed TRAIL and compared it to the effects
of rTR. We found MSCs to be completely resistant to rTR as well as
the adenoviral vector-encoded full-length membrane bound form on
the surface, whereas HCT116 cells, our positive controls, are
driven into apoptosis by rTR (Fig. 2D). To evaluate whether MSCs
transduced with Ad.TR were capable of inducing apoptosis in A549
cells, coculture experiments were performed. MSCs were seeded at
105 cells per well and transduced with adenovirus. After 24 hrs
MSCs were trypsinized and counted. 104 of Ad-transduced or
untransduced MSCs (i.e. 1 MSC per 10 seeded A549 cells) were
then added to each well containing A549 cells. After 48 hrs, the
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Fig. 1 Adenovirally expressed TRAIL induces higher levels of apoptosis than recombinant TRAIL in A549 cells. (A) Replication-defective adenoviral
vectors with deletions of the E1 and E3 regions (Ad.E1 and Ad.E3) were used in our study. They expressed TRAIL (Ad.TR), -galactosidase
(Ad.BGal) or EGFP (Ad.EGFP) from the cytomegalovirus (CMV) promoter (P-CMV). Other elements are the 5 and 3 inverted-terminal-repeats (ITR)
and the thymidine kinase polyA-addition signal (TKpA). (B) A549 cells were seeded at 105 cells per well overnight. Adenovirus (expressing TRAIL or
-galactosidase, Ad.TR and Ad.BGal, respectively) was added at 1, 10 or 100 pfu/cell or recombinant TRAIL (rTR) was added at 1, 5 or 10 ng/ml. As
positive control for the effects of rTR human colorectal cancer HCT116 cells were treated with 10 ng/ml rTR. Cells were assayed for apoptosis after
48 hrs by Nicoletti hypodiploidity assay. Samples were analysed by flow cytometry. Numbers represent mean values of five samples ± standard 
deviation. **P < 0.001.
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Fig. 2 Transgene expression after adenovirus transduction of MSCs. (A) MSCs were transduced with Ad.EGFP and Ad.TR at 100 pfu and were analysed
by fluorescent and phase contrast microscopy 48 hrs later. The images show that green fluorescent expression was established in Ad.EGFP-trans-
duced cells. Transduction with Ad.EGFP and Ad.TR did not alter the morphology of MSCs as compared to untransduced cells. (B) EGFP transgene
expression was also quantified by FACS analysis. MSCs were transduced with Ad.EGFP at 100 pfu/cell. Almost all cells were transduced after 48 hrs.
(C) Cell lysates from MSCs transduced with Ad.BGal or Ad.TR were probed for TRAIL expression by Western blotting and compared to signals from
rTR that was loaded at 5, 20 and 30 ng on the same gel. The Ad.TR-encoded full-length membrane-bound form runs at 30 kD, whereas the soluble
rTR, representing only the ectodomain of TRAIL, runs at 20 kD. A CuZnSOD Western blot serves as loading control for the protein lysates from Ad.BGal
and Ad.TR-transduced cells (D) Neither treatment with rTR nor transduction with Ad.TRAIL causes apoptosis in MSCs. MSCs were either treated with
rTR at concentration of 10 ng or transduced with Ad.TRAIL (100 pfu/cells) or Ad.BGal (100 pfu/cells). Specific apoptosis was measured 48 hrs later
by Nicoletti hypodiploidity assay. HCT116 cells (white bar) treated with rTR serve as positive control.
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wells were assayed for apoptosis. In wells containing Ad.TR-
transduced MSCs levels of apoptosis were approximately 27%
above background with no appreciable difference between the lev-
els of apoptosis in untreated wells or wells containing untrans-
duced or Ad.BGal-transduced MSCs (Fig. 3A). In order to test that
apoptosis was indeed caused by TRAIL and not some other prop-
erties of the Ad.TR-transduced MSCs, we cotreated with neutraliz-
ing  anti-TRAIL antibody and the pan-caspase inhibitor zVAD. Both
cotreatments were able to significantly reduce or even block the
MSC.TRAIL-induced apoptosis in A549 cells (Fig. 3A). Due to the
differences in the growth rates of both cell types (MSC doubling
time approximately 2.3 days, A549 doubling time approximately
1.2 days) it was desirable to determine the relative numbers of
each cell type in the coculture system. A549 cells and MSCs were
prepared using enzyme-free cell dissociation buffer (Specialty
Media, NJ, USA) and stained for CD105 (endoglin), a marker for
endothelial cells and bone marrow-derived stromal cells. A549
cells were only approximately 0.4% positive for this marker above
isotype controls, whereas MSCs were approximately 98% positive
for this marker above isotype controls. MSCs, untransduced and
transduced with Ad.Bgal were cocultured with A549 cells as previ-
ously described and wells were assayed for CD105 expressing cells
after 48 hrs. The levels of CD105 cells in wells containing MSCs
untransduced or Ad.BGal transduced were similar and were only
approximately 1% above the levels observed in wells containing
A549 cells alone. This suggests that MSCs untransduced or trans-
duced with adenovirus represented only approximately 1% of the
final cell population in the assay system being employed here and
that the measured apoptosis stemmed almost exclusively from A549
cells (Fig. 3B). In order to assess whether lower concentrations of
MSCs per well could be employed, MSCs transduced with Ad.TR
were cocultured with A549 cells seeded as before. 104 (1:10) and 3.3
 103 (1:30) MSC cells were added per well. Cells were assayed for
apoptosis after 48 hrs. There was a trend towards lower levels of
apoptosis in wells cultured at a 1:30 ratio than at the 1:10 ratio, how-
ever, this was not significant (Fig. 3C). In order to check that
MSC.TRAIL did not have detrimental effects on normal, non-tumour
cells we cocultured human primary fibroblasts with MSCs loaded
with TRAIL. Figure 3D shows that MSCs loaded with TRAIL did not
induce apoptosis in fibroblasts indicating that the use of TRAIL-
expressing MSCs is principally safe.
Given the surprisingly high-apoptosis induction activity, we
addressed whether the effect was solely caused by TRAIL-
displayed on MSCs or whether other mechanisms such as virus
transfer from MSC to target cells (A549) might also account for
the observed cell-killing effect. To this end, we mixed Ad.EGFP-
transduced MSCs with A549 cells and measured the green fluo-
rescence in A549 cells 48 hrs later.
MSCs transduced with Ad.EGFP transfer virus 
and transgene expression to neighbouring cells
When performing coculture experiments using MSCs that had
been transduced with Ad.EGFP, we noticed that higher numbers of
cells were EGFP positive in this assay system than could be
accounted for by MSCs alone. Therefore, to determine whether
the MSCs were delivering Ad.EGFP to A549 cells, MSC cells
were untransduced or transduced with Ad.EGFP at 10, 100 or
1000 pfu/cell. After 48 hrs, MSCs were prepared for addition to
wells containing A549 cells as previously described, however,
prior to being added the final MSC cell suspension was cen-
trifuged and the supernatant was aspirated. The cell pellet was
then washed and re-suspended in the equivalent volume of
medium to the aspirated supernatant. 104 untransduced and
Ad.EGFP-transduced MSCs or an equivalent volume of medium
from the supernatant samples was then added to wells containing
A549 cells. Cells were assayed for EGFP expression by flow
cytometry after 48 hrs. The wells with MSCs infected at 1000
pfu/cell contained approximately 47% positive EGFP cells, while
the wells to which MSCs infected at 100 and 10 pfu/cell contained
approximately 14% and 1% EGFP positive cells, respectively. In
the wells to which the supernatants had been added only those
from the 1000 pfu/cell infected MSCs had levels of EGFP positive
A549 cells above background of approximately 0.7%. This sug-
gests that MSCs can transfer virus to A549 cells and that the EGFP
positive A549 cells were not the result of free virus being carried
over in the medium supernatant (Fig. 4A). To assess whether the
EGFP positive cells were the result of virus genome transfer result-
ing in production of novel transgenic protein or were due to the
transfer of EGFP protein between MSC cells and A549 cells, the
following experiment was performed. MSCs were untransduced or
transduced with Ad.BGal (100 pfu/cell) and harvested after 48 hrs.
104 untransduced or Ad.BGal-transduced MSCs were added to
wells that had been seeded the previous day with 105 293 cells
(which is a producer cell line for adenovirus). After 24 hrs, cells
were harvested and DNA was extracted. Numbers of viral
genomes were quantified by quantitative PCR. Wells containing
MSCs transduced with adenovirus and cocultured with 293 cells
had approximately 100-fold higher numbers of adenoviral
genomes than adenovirus-transduced MSCs cultured alone indi-
cating that MSCs transferred adenovirus over to 293 cells, which
replicated the virus resulting in higher genome numbers (Fig. 4B).
Untransduced MSCs cultured with 293 cells did not contain any
detectable adenoviral genomes (Fig. 4B). All adenoviral vectors
were found negative for replication competent adenovirus (RCA)
by PCR analyses prior to their use ruling out replication inside the
MSCs as a source for the viral vectors that ‘re-transduced’ (or
‘post-transduced’) the A549 and 293 cells in our experiments.
Furthermore, we examined MSCs as well as MSCs transduced
with Ad.EGFP for E1A expression by Western blot to test whether
virus could be replicated in MSCs. However, in contrast to our
positive control, 293 cells, we could not detect E1A protein in
MSCs (Fig. 4C). Taken together, our data demonstrate that our
adenoviral vectors are RCA-free and that they do not replicate
inside MSCs. Thus, MSCs are able to convey the genetic informa-
tion carried by adenoviral vectors onto target tumour cells by 
an unknown mechanism, thereby potentially increasing the efficacy
of therapeutic transgenes such as TRAIL beyond the expression
on the surface of MSCs alone. Next, we investigated whether
J. Cell. Mol. Med. Vol 12, No 6B, 2008
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Fig. 3 MSCs transduced with Ad.TR can induce apoptosis in A549 cells. (A) MSCs were transduced with Ad.BGal (100 pfu/cell) or Ad.TR 
(100 pfu/cell). After 48 hrs MSCs were trypsinized and 104 of these cells were added to wells that had been seeded the day before with A549 cells at
105 cells per well. After 48 hrs, wells were trypsinized and the complete mixed cell population was measured by Nicoletti apoptosis assay. A549 cells 
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and MSCs cultured alone as well as A549 cells mixed with MSCs transduced with Ad.BGal showed only background apoptosis of below 5%. In con-
trast, in A549 mixed with MSCs transduced with Ad.TR apoptosis rates of almost 30% could be measured. This apoptosis could be inhibited by TRAIL
neutralizing  antibodies (-TR-ab) and the pan-caspase inhibitor zVAD. Numbers represent mean values of three samples ± standard deviation. 
**P < 0.001. (B) MSCs cocultured with A549 cells represent approximately 1% of the final cell population. 104 untransduced or Ad.BGal transduced
(100 pfu/cell) MSC cells were added to wells that were unseeded or had been seeded the previous day with 105 A549 cells. After 48 hrs, cells were
detached from wells using trypsin free buffer (Specialty Media, NJ, USA). Cells were stained with anti-CD105 and analysed by flow cytometry. The iso-
type control for a 1:10 MSC:A549 mix (MSC+A549 ISO) was, as expected, negative for CD105, whereas 98% of all cells in a pure MSC culture (MSC)
were CD105 positive. A549 cells only (A549) showed a weak CD105 signal in 0.5% of all cells. In 1:10 mixes with MSCs (MSC+A549) or MSCs trans-
duced with Ad.BGal (A549+MSCGal) the CD105 signal increased to about 1.5% 48 hrs after mixing and coculturing. Please note that graph is
depicted in log-scale. (C) The experiment was performed as described above (Fig. 3A), however, untransduced and transduced (Ad.BGal and Ad.TR)
MSC cells were added at 104 (1:10) (black bars) and 3.3  103 (1:30) (white bars) cells per well. After 48 hrs, cells were analysed by Nicoletti apop-
tosis assay proving that even at a lower ratio against the target cancer cells, MSCs expressing TRAIL can trigger significant levels of apoptosis.
Numbers represent mean values of 12 samples ± standard deviation. **P < 0.001. (D) MSCs were transduced with Ad.EGFP (100 pfu/cell) (black bars)
or Ad.TR (100 pfu/cell) (white bars). After 48 hrs, MSCs were harvested and 104 of these cells were mixed with 105 pre-seeded primary human fibrob-
lasts (Fib). After 48 hrs, apoptosis was determined by Nicoletti apoptosis assay. HCT116 cells (HCT) served as positive controls in this experiment.
Fig. 4 Ad.EGFP-transduced MSCs transfer aden-
oviral-encoded transgene expression onto A549
cells. (A) MSC cells were transduced with Ad.EGFP
at 10, 100 or 1000 pfu/cell. After 48 hrs MSCs
were trypsinized and prepared as previously
described. Before addition to A549 seeded wells
the Ad.EGFP-transduced MSC cell suspension was
centrifuged. The supernatant was removed from
the cell pellet and also added to A549 cells (white
bars, which are hardly visible except for 1000 pfu).
This resulted in almost no transduction, indicating
that no virus was left in the supernatant medium
or produced in the MSCs. The MSCs themselves
were re-suspended in a volume of medium equiv-
alent to that of the aspirated supernatant. 104
Ad.EGFP-transduced MSCs (black bars) were
added to wells seeded with A549 cells. Samples
were assayed for EGFP expression by flow cytom-
etry after a further 48 hrs. (B) Adenovirus-trans-
duced MSC cocultured with 293 cells results in
novel virus genome production. MSCs were trans-
duced with Ad.BGal (100 pfu/cell) or left untreated.
After 48 hrs, untransduced (MSC+293) and Ad-
transduced MSCs (MSC Ad.+293) were cocultured
with 293 cells that had been seeded the previous
day at 105 cells/well or Ad.BGal-transduced MSCs
were replated into wells containing no 293 cells
(MSC Ad.). After 24 hrs, cells were harvested and
DNA was extracted. Cells were analysed for viral
DNA content by quantitative PCR using primers
specific for the knob turn region of the virus and
the SYBR Green quantitative PCR system.
Samples were run on an ABI Prism 7000 sequence
detector. Please note that the graph is depicted in
log-scale. (C) In order to rule out that our MSCs
expressed adenoviral E1A and could facilitate virus
replication, we performed a Western blot on pro-
tein lysates from MSCs, MSCs transduced with
Ad.EGFP (0, 48, 72 and 96 hrs after transduction) and 293 cells as positive control. Only 293 cells showed a signal for E1A. A CuZnSOD Western blot
was carried out as loading control.
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Ad.TR-loaded MSCs would be recognised and inhibited by
immune-effector cells.
Ad.TR-transduced MSCs do not stimulate 
T-cell proliferation
In order to evaluate whether MSCs transduced with adenoviral
vectors (and in particular Ad.TR) were more immunogenic and
would stimulate a T-cell response, MSCs untransduced and trans-
duced with Ad.BGal or Ad.TR were cocultured with carboxyfluo-
rescein diacetate succinimidyl ester (CFSE) stained PBMCs from a
donor with high levels of anti-adenovirus antibodies. In order to
assess whether any lack of T-cell proliferation was due to factors
released by MSCs, the same experiments were performed using
fibroblasts instead of MSCs. Neither Ad.BGal transduced nor
Ad.TR-transduced MSCs (or fibroblasts) induced a T-cell prolifer-
ation response significantly above background (Fig. 5). When
PBMCs were stimulated with CD3/CD28 expressing beads over
90% proliferation was observed serving as positive control.
The presence of white blood cells or erythrocytes
does not inhibit Ad.TR-transduced MSCs from 
inducing apoptosis in A549 cells
In order to determine whether MSCs transduced with Ad.TR
could induce apoptosis in A549 cells in an environment approxi-
mating that of the blood stream, WBCs and washed blood cells
(whole blood that was washed and pelleted four times in excess
PBS, cellular content approximately 99.9% erythrocytes) were
prepared. These cells were overlaid onto A549 cells that had been
stained with Cell Tracker Green (Molecular Probes) and seeded at
105 cells per well. MSCs were untransduced or transduced with
Ad.BGal (100 pfu/cell) or Ad.TR (100 pfu/cell) and harvested after
48 hrs. These cells were then added to medium, washed blood or
WBC containing wells at 104 cells per well. The wells were har-
vested after 48 hrs and the medium and WBC containing samples
were prepared for Nicoletti assay. The wells containing washed
blood cells were harvested and the red blood cells were lysed by
exposure to a hypotonic solution before being prepared for
Nicoletti assay. MSCs transduced with Ad.TR-induced levels of
apoptosis in A549 cells significantly above background both in
the presence of washed blood cells (Fig. 6A) and WBCs (Fig. 6B).
The background levels of apoptosis were increased in wells con-
taining washed blood cells and WBCs compared to those of
A549s cultured in medium alone. However, under both conditions
(presence of washed blood cells or WBCs) there were increases
in apoptosis induction in A549 cells exposed to MSCs transduced
with Ad.TR. In samples containing washed blood cells the
difference between Ad.BGal and Ad.TR-transduced MSCs was
approximately 13% (Fig. 6A). In samples containing WBCs, the
difference between controls and Ad.TR-transduced MSCs was
approximately 35% (Fig. 6B).
The presence of serum, containing anti-adenovirus
antibodies, does not block MSC-mediated Ad.EGFP
transfer or TRAIL-induced apoptosis induction
Next, we wanted to know whether adenovirus-neutralizing  anti-
bodies could interfere with the transfer of adenoviral vector and
Fig. 5 Transduction of MSCs with adenovirus does not induce T-cell
proliferation. Peripheral blood mononuclear cells (PBMCs) were isolated
by Ficoll gradient from blood samples taken from a healthy donor.
PBMCs were then stained with carboxyfluorescein diacetate succin-
imidyl ester (CFSE) dye and left overnight in PBMC culture medium.
MSCs and fibroblasts were untransduced or transduced with Ad.BGal
(100 pfu/cell) or Ad.TR (100 pfu/cell) (MSC, MSCGal, MSCTR and Fib,
FibGal, FibTR) and harvested after 48 hrs. 104 MSCs were cocultured
with 105 PBMCs for 5 days. As a positive control, PBMCs were also
stimulated by the addition of 2.5 l CD3/CD28 beads (Dynal,
Invitrogen). Cells were then collected and analysed by flow cytometry
for cell proliferation, gating on the lymphocyte population. Please, note
that graph is depicted in log-scale.
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transgene information to target cells as described in Fig. 4 or
could block the apoptosis-inducing activity of MSCs loaded with
Ad.TR. First, we tested the sera of 18 donors for the presence
and activity of anti-adenovirus antibodies and identified a num-
ber of sera with high and low adenovirus-neutralizing  antibody
levels. In Fig. 7A, one serum with high adenovirus-neutralizing
antibody levels (Serum A) and one with low adenovirus-neutral-
izing  activity (Serum B) are shown. Pre-incubation of Ad.EGFP
Fig. 6 Ad.TR-transduced MSCs induce apoptosis in A549 cells in the presence of washed blood (erythrocytes) and white blood cells at physiologi-
cal concentrations. MSCs were untransduced or transduced with Ad.BGal (100 pfu/cell) or Ad.TR (100 pfu/cell) (MSC, MSCGal, MSCTR) and har-
vested after 48 hrs. A549 cells were stained with cell tracker green and seeded into wells at 105 cells per well. Once these cells had adhered to the
tissue culture wells (A) white blood cells were added at a concentration of 3  106 cells/ml or (B) washed blood cells were added at approximately
5  109 cells/ml. 104 untransduced or Ad-transduced MSC cells were added to each well. After 48 hrs, washed blood cells (A) or white blood cells
(B) and medium alone containing wells were harvested and prepared for Nicoletti assay. The wells containing washed blood cells were harvested and
the red blood cells were lysed by exposure to a hypotonic solution before these samples were prepared for Nicoletti assay. All samples were assayed
by flow cytometry gating on the cell tracker green positive population alone. Overall, the level of apoptosis in white blood cell and 
washed blood exposed wells was increased, however, samples exposed to Ad.TR-transduced MSCs were consistently higher than background or con-
trols. Numbers represent mean values of three experiments ± standard deviation. *P < 0.05; **P < 0.001.
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cells to induce apoptosis in A549 cells. MSC cells were untransduced (MSC) or transduced with Ad.BGal (MSCGal) or Ad.TR (MSCTR) with 100 pfu/cell. A549
cells that were treated with serum only are shown on the left (serum). After 24 hrs, the cells were harvested and incubated in neat serum for 30 min. at 37C.
The cell suspension (104 MSC cells/well) and serum were then added to wells containing A549 cells seeded the previous day. After 48 hrs, samples were pre-
pared for Nicoletti assay and analysed by flow cytometry. Numbers represent mean values of duplicate samples ± standard deviation. *P < 0.05.
Fig. 7 Comparison of neutralization properties of different human sera. (A)
107 Ad.EGFP pfu were incubated in complete RPMI medium (white bar) or
human serum (black bars) diluted 1/10 or 1/100 in complete RPMI medium
for 30 min. at 37C. Data shown are samples with high (Serum A) and low
(Serum B) adenovirus-neutralizing activities chosen from a panel of 18
donors. After pre-incubation of Ad.EGFP with medium and the two sera, the
samples were added to wells containing A549 cells seeded the previous day
at 105 cells per well. After 48 hrs, the cells were harvested and analysed for
EGFP expression by flow cytometry. While A549 cells are readily transduced
with Ad.EGFP pre-incubated in RPMI medium (white bar), pre-incubation
with Serum A at both concentrations completely neutralizes the transduction
activity of the adenoviral vector. Serum B, on the other side allows transduc-
tion of A549 cells after pre-incubation Numbers represent mean values of
duplicate experiments. (B) Exposing MSCs transduced with Ad.EGFP to neat
human serum with high levels of adenovirus neutralizing  antibodies (Serum
A) does not inhibit the ability of these cells to ‘post-transduce’ A549 cells.
MSC cells were transduced with Ad.EGFP (100 pfu/cell). After 48 hrs, the
cells were harvested and incubated in neat serum or serum diluted 1:10 or
1:100 in complete DMEM medium for 30 min. at 37C. Samples were pre-
pared using serum from a high neutralizing  donor (Serum A; white bars) and
a low-neutralizing  donor (Serum B; black bars). 104 MSCs including the
serum were then added to wells containing A549 cells seeded the previous
day. After 48 hrs, samples were prepared for analysis by flow cytometry. This
analysis shows that A549 cells were transduced by the Ad.EGFP-loaded
MSCs regardless of the concentration of adenovirus-neutralizing  antibodies.
Numbers represent mean values of three samples ± standard deviation. (C)
Exposing MSCs transduced with Ad.TR to neat human serum with high lev-
els of adenovirus neutralizing  antibodies does not inhibit the ability of these
Fig. 8 MSCs transduced with Ad.TR give rise to tumour growth reduction in vivo. (A) Immune-deficient mice were injected with 5  106 A549 cells
into the right flank. After 1 week when tumours were approximately 100 mm3 in size, 1  106 MSCs either transduced with Ad.TR or Ad.EGFP were
directly injected into the tumour. The tumour growth was followed over 3 weeks. This is depicted in the graph. Numbers represent mean values of five
animals in each group ± standard deviation. **P < 0.001 (B) Representative tumours of two animals are shown after dissection clearly showing the
smaller size in the animal from the group treated with Ad.TR-transduced MSCs.
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in Serum A could block transduction of A549 cell, which are
otherwise readily transduced as shown in the medium control
on the left (Fig. 7A). Serum B on the other hand had some
inhibitory effect on the transduction efficiency at a dilution of
1:10, which is probably due to the non-specific blocking effect
of serum proteins at this high concentration, but almost com-
pletely lost this inhibitory effect at a 1:100 dilution (Fig. 7A).
Having identified high and low adenovirus-neutralizing  anti-
body containing sera, we set out to ascertain whether MSCs trans-
duced with adenovirus could ‘post-transduce’ (see Fig. 4) A549
cells in the presence of human serum. Ad.EGFP-transduced MSCs
(100 pfu/cell) were again exposed to sera from two donors, one
with high adenovirus-neutralizing  antibody levels (Serum A) and
one low adenovirus-neutralizing  antibody levels (Serum B). The
sera were used undiluted (neat), or at 1:10 and 1:100 dilutions and
the cells were incubated in the serum preparations for 30 min. at
37C. The cell suspensions were then overlaid onto A549 cells.
After 48 hrs, the cells were harvested and analysed for EGFP expres-
sion by flow cytometry (Fig. 7B). The results from both donors
were almost identical. This means exposure to high- or low-neu-
tralizing  sera did not decrease the efficiency of MSC-mediated
transduction of A549 cells with Ad.EGFP. Hence, the piggy-backing
of adenovirus by MSCs cannot be inhibited by neutralizing  anti-
bodies and this effect might be able to increase the effectiveness
of MSC gene therapy strategies. However, further and stringent
tests have to be performed in the future to confirm the existence
and usefulness of this effect in vivo.
In order to assess whether serum could block MSC.TRAIL-
mediated apoptosis induction in A549 cells, MSCs were untrans-
duced or transduced with Ad.TR or Ad.BGal and incubated with
neat serum for 30 min. at 37C. MSCs transduced with Ad.TR
induced approximately 18% higher levels of apoptosis in A549
cells than MSCs transduced with Ad.BGal (Fig. 7C).
MSCs transduced with Ad.TR inhibits the growth
of A549 xenografts in mice
We next wanted to know whether MSCs transduced with TRAIL
would also have anti-tumour activity in vivo. Therefore, we
injected 5  106 A549 cells into nu/nu mice. When the resulting
tumours had reached an average volume of 100 mm3 after 1 week,
1  106 MSC.TRAIL cells in 100 l PBS were injected into the
tumour mass. As controls tumours were injected with MSC.EGFP
cells. Figure 8A shows the growth curve of the tumours over a
period of 3 weeks following MSC.TRAIL and MSC.EGFP injections.
During this period, MSC.EGFP-treated tumours grew to about
three times the size compared to the beginning of the MSC-injec-
tions, whereas MSC.TRAIL-treated tumours only grew by a factor
of 1.25, almost completely arresting the tumour growth. Figure 8B
shows representative tumours after the conclusion of the experi-
ment. In conclusion, MSCs expressing TRAIL possess tumourici-
dal activity in vivo.
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Discussion
In this paper, we demonstrate the potential of MSC- borne, virally
expressed TRAIL to induce apoptosis in A549 cells in the context
of the blood environment. A549 cells are traditionally described as
a TRAIL resistant cell line [35] and only low levels of apoptosis
were observed in cells treated with up to 10 ng/ml rTR. However,
transduction of A549 cells with Ad.TR resulted in high levels of
apoptosis in these cells in agreement with data described by Seol
et al. [34]. Though the ability of Ad.TR to overcome TRAIL resist-
ance in a range of cell lines has been explored no clear mechanism
has been elucidated [36–38]. While administration of TRAIL pro-
tein or TRAIL receptor agonistic antibody may have potential for
cancer therapy [26, 27], it lacks many of the potential benefits that
may be gained by using a gene therapy strategy for the production
of the protein. Nakamizo et al. [8] demonstrated the increased effi-
cacy of IFN- expression from MSCs over intravenous injection of
IFN- protein. In a similar manner production of TRAIL from cells
localized to the tumour may enhance the effects of the therapy.
MSCs have been shown to have very low levels of active TRAIL
receptors and doses of up to 50 ng/ml rTR were shown not to
induce apoptosis in MSCs (manuscript in preparation).
Ad.TR-transduced MSCs were capable of seeding in A549 cell
monolayers and could effectively induce apoptosis in the latter. It
has been shown that cell-to-cell contact is required to mediate a
TRAIL bystander effect [37]. In this experimental system, approxi-
mately 1% of the final cell population were MSCs and these cells
were responsible for inducing apoptosis in approximately 27% of
the final cell population after 48 hrs. Interestingly, Ad.EGFP-trans-
duced MSCs appeared to transfer the virus to A549 cells. An
important consequence of this result may be that transduced MSCs
mediate a bystander effect, in which they transfer virus to neigh-
bouring cells resulting in adenoviral transgenic protein production
by these cells. In the case of TRAIL, this second round of protein
production may substantially increase the tumour cell-killing effect.
However, this remains to be addressed in detailed studies in the
future. While some evidence argues for carry-over of virus attached
to the surface of MSCs, other alternative or additional mechanisms
might account for this bystander effect. For example membrane-
derived microvesicles containing mRNA and/or protein have been
described as a way to transfer genetic information or their products
from one cell to another [39–41]. Such a mechanism could explain
how MSCs transfer EGFP (mRNA and/or protein) to the A549 tar-
get cells in our experiments.
The treatment of metastatic cancer ideally would be achieved
through the introduction of the therapeutic vector into the blood
stream from where it would actively seek out tumour sites that may
be otherwise inaccessible or undetectable by the clinician.
However, many previous adenovirus-based strategies have been
hampered by the innate and adaptive immune response [12–14,
17]. A cytotoxic T-cell response against adenoviral antigens dis-
played on the surface of the transduced MSCs may result in the
destruction of the cells before they can be therapeutically effective.
Addition of adenovirus-transduced MSCs to PBMCs did not induce
an immune response and Ad.TR-transduced MSCs and fibroblasts
had lower levels of proliferation than untransduced or Ad.BGal-
transduced controls. This is potentially due to the ability of virally
expressed TRAIL ligand to induce apoptosis in proliferating T cells.
Other factors that may be responsible for blocking MSC delivery of
therapeutic agents to the tumour site include WBCs and erythro-
cytes. Erythrocytes have been shown to bind adenovirus and at
physiological concentrations will inhibit transduction of an A549
cell monolayer by over 200-fold [17]. Importantly, the presence of
these cells at physiological concentrations had very little effect on
Ad.TR-transduced-MSC-mediated apoptosis induction in A549
cells. In the blood stream, serum components such as antibodies
may neutralize viral vectors. However, even at serum concentra-
tions 10-fold in excess of those required to neutralize high MOIs
(100 pfu/cell) of adenovirus, no inhibition of MSC-mediated aden-
ovirus transfer was observed. Also, MSCs transduced with Ad.TR
could also effectively induce apoptosis in A549 target cells.
The ability of MSCs to piggy-back adenovirus, while shielding it
from neutralizing  antibodies, to neighbouring cells is an interest-
ing and potentially important finding in the drive to develop a sys-
temically administered gene therapy vehicle. Furthermore, the
capacity of MSCs transduced with adenovirus expressing TRAIL
for inducing apoptosis in A549 lung epithelial cancer cells in the
presence of serum, WBCs and erythrocytes supports the potential
of these cells to become an exciting new delivery vector for the tar-
geted treatment of cancer and lung cancer in particular, as MSCs
preferentially home to the lung [42].
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